{'fraction_non_alphanumeric': 0.04142011834319527, 'fraction_numerical': 0.027049873203719356, 'mean_word_length': 5.365591397849462, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Comparing the frequency of CD33+ pSTAT3+ myeloid‐derived suppressor cells and IL‐17+ lymphocytes in patients with prostate cancer and benign prostatic hyperplasia

Prostate cancer (PCa) is one of the most epidemic types of cancer in men. The tumor microenvironment (TME) of PCa is involved in the emergence of immunosuppressive factors such as myeloid‐derived suppressor cells (MDSC), which regulate the immune system by several mechanisms, including interleukin (IL)‐10 production. On the other hand, IL‐17+ helper T cells (Th17) induce MDSCs and chronic inflammation in TME by producing IL‐17. This study demonstrated that the frequency of CD33+ pSTAT3+ MDSC and IL‐17+ lymphocyte as well as IL‐10 messenger RNA (mRNA) expression were significantly higher in the PCa patients than in the benign prostatic hyperplasia (BPH) group. Moreover, there was no significant relationship between the frequency of CD33+ pSTAT3+ MDSC, and IL‐17+ lymphocyte with Gleason scores in the PCa group. We suggested that the higher frequency of CD33+ pSTAT3+ MDSC and IL‐17+ lymphocyte and the more frequent expression of IL‐10 mRNA in PCa patients may play roles in tumor progression from BPH to PCa.